Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024)
Zoetis' (ZTS) quarterly Income from Non-Controlling Interests came in at $10.0 million in Q3 2024, up 600.0% on a QoQ basis from -$2.0 million in Q4 2023.
Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024) Analysis & Trends
Zoetis (ZTS) has 12 years of Income from Non-Controlling Interests data on file, last reported at $10.0 million in Q3 2024.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $10.0 million in Q3 2024; TTM through Jun 2025 was $10.0 million, a 600.0% increase from a year earlier, with the FY2024 full-year figure at $10.0 million, up 350.0% from the prior year.
- Income from Non-Controlling Interests for Q3 2024 stood at $10.0 million, up from -$2.0 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ZTS reached as high as $10.0 million in Q3 2024 and fell as low as -$2.0 million in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged -$166666.7 across 5 years, with a median of -$1.0 million in 2020.
- Across the five-year window, Income from Non-Controlling Interests changed 0.0% in 2021 and sank 100.0% in 2023, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$1.0 million in 2020, then changed by 0.0% to -$1.0 million in 2021, then changed by 0.0% to -$1.0 million in 2022, then sank by 100.0% to -$2.0 million in 2023, then jumped by 600.0% to $10.0 million in 2024.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $10.0 million in Q3 2024, -$2.0 million in Q4 2023, and -$1.0 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 10.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | -1.00 Mn |
| Dec 31, 2022 | -1.00 Mn |
| Sep 30, 2022 | -1.00 Mn |
| Mar 31, 2022 | -1.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | -1.00 Mn |
| Dec 31, 2020 | -1.00 Mn |
| Jun 30, 2020 | -1.00 Mn |
| Jun 30, 2018 | -2.00 Mn |
| Mar 31, 2018 | -2.00 Mn |
| Dec 31, 2017 | -1.00 Mn |
| Oct 1, 2017 | -2.00 Mn |
| Apr 2, 2017 | 1.00 Mn |
| Oct 2, 2016 | -2.00 Mn |
| Dec 31, 2015 | -2.00 Mn |
| Sep 27, 2015 | 1.00 Mn |